A major new research project in Denmark is taking aim at a serious and growing form of heart disease known as HFpEF—heart failure with preserved ejection fraction. Backed by a record DKK 473 million (USD 72.4 million) grant from the Novo Nordisk Foundation, the CAPTURE project will use advanced data tools, including AI, to study up to 30,000 people across Denmark.

HFpEF is linked to conditions such as diabetes, obesity, and high blood pressure and affects millions worldwide. It’s especially difficult to diagnose and treat, often resulting in long hospital stays and a significantly increased risk of early death.

“This is the largest clinical research grant we’ve ever awarded,” said Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation. “Our goal is to find better ways to detect and treat HFpEF before it leads to severe complications.”

The seven-year national study brings together researchers and hospitals from all five of Denmark’s healthcare regions and is expected to shape the future of heart care both locally and globally.

For more information, please visit:

captureheart.dk
Site is in Danish. Your browser may prompt you to translate the page into your local language.

Video about CAPTURE:
https://vimeo.com/1090376132